ASCO Annual Meeting Coverage
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The American Society of Clinical Oncology annual meeting for 2024 takes place in Chicago from 31 May to 4 June. This page is your one-stop shop for all of Scrip's conference coverage, including preview and post-meeting analysis. You can also find archive content from previous meetings here.
![](/-/media/editorial/scrip/2024/06/asco_2024/sc2406_ascoexhibithall_1200.jpeg?rev=0916ba88e2a14c1bb6ea6fc085c4d244&w=350&hash=1AF44A275F143B1DD7FADAB4EB584605)
TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up
Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.
![](/-/media/editorial/stock-images/abstract/sc2406_threewayrace_86281384_1200.jpg?rev=d1afdd1cb7284f9db5d7fa383592d1fd&w=350&hash=8A0A5E9EF0A62DDA8B2AD4487DAE872C)
Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease
The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers.
![](/-/media/editorial/scrip/2024/06/asco_2024/sc2406_asco_image3_1200.png?rev=28f716603be74b3cbf3cfc928adda29e&w=350&hash=ECEA63C2C5AA2C7BAC1C2F239F096923)
ASCO 2024 Wrap-Up Podcast
Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.
![](/-/media/editorial/scrip/00_regular-column-images/chinesebiotech_podcast_1200.jpg?rev=d3d2a7761a5b4b608755f8bc405705b6&w=350&hash=0937111524C56EFA47CE6E840881483D)
China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights
US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.
![](/-/media/editorial/scrip/2024/06/sc2406_ovarian_2161724253_1200.jpg?rev=5f198007946d446481cb7e125f126173&w=350&hash=8C42D4A5C498946296D5BD73DA524ED3)
ASCO: Simcere Targets Suvemcitug OS Win In Platinum-Resistant Ovarian Cancer
In a late-breaker oral presentation at ASCO on the SCORES study with suvemcitug, Simcere revealed a trend favoring an overall survival advantage in platinum-resistant oral cancer, despite immature data.
![](/-/media/editorial/scrip/2024/06/sc2406_attention_737529970.jpg?rev=c91088600ff7456da88d3ad349408f9a&w=350&hash=9F9F63422B078F8405915A70CCDA868E)
ASCO: Favorable Data For J&J Combo in 1L NSCLC Gain Attention
Positive new and updated data at ASCO for Rybrevant plus lazertinib could position the combo more strongly against Tagrisso in the first-line treatment of high-risk, EGFR-mutated non-small lung cancer.
![](/-/media/editorial/scrip/2024/06/asco_2024/sc2406_ascoexhibithall_1200.jpeg?rev=0916ba88e2a14c1bb6ea6fc085c4d244&w=350&hash=1AF44A275F143B1DD7FADAB4EB584605)
ASCO: Regeneron Shows Early Bispecific Antibody Efficacy In Hard-To-Treat Colorectal Cancer
Scrip talked to Regeneron at ASCO about REGN7075 and Regeneron’s bispecific development strategy in solid tumors.
![](/-/media/editorial/buildings/government_us-and-international/mccormick-place-1200-shutterstock_1146193799.jpg?rev=a63a74aeb5ce4fe48d825209a099bff9&w=350&hash=13C4E2412CED7812A71FB53DA4845597)
ASCO: AstraZeneca Achieves Eye-Catching Solid Tumor Results With 'Armored' CAR-T
Solid tumor CAR-T may succeed AZD7003 where many others have failed as the firm builds its cell therapy pipeline.
![](/-/media/editorial/scrip/2023/08/sc2305_lung_cancer_new_1765829399_1200.jpg?rev=a91f1481a9224f3bbe9fb036e1b61cda&w=350&hash=DDD5264DBC8445B534387BAA8C45FC5B)
ASCO: Ivonescimab A New Challenger To Keytruda In 1L, PD-L1-High NSCLC?
Backed by strong progression-free survival results from the China-only, head-to-head HARMONi-2 trial, Akeso/Summit’s ivonescimab could be set to become a global contender against established standard of care Keytruda in first-line, PD-L1-high non-small cell lung cancer.
![](/-/media/editorial/scrip/2024/06/asco_2024/sc2406_asco_image2_1200.png?rev=461047a9091d4de4b50210ba27e459fd&w=350&hash=0FE0CE54D0F588966165377C66AE5FAE)
ASCO Roundup: Looking For The Future Of Cancer Research
As the American Society of Clinical Oncology annual meeting drew to a close, Scrip spoke with industry execs about staying competitive, adjusting to policy changes and how artificial intelligence is advancing cancer R&D.
![](/-/media/editorial/scrip/2024/06/asco_2024/sc2406_asco_image16_astellas_1200.png?rev=d02c1d26f2944a16b8cb542d9bd46efb&w=350&hash=B0E54A850C31FE203AF92B24EFC82ECC)
ASCO: As FDA’s Zolbetuximab Decision Looms, Astellas Looks To Meet Testing Challenge
Scrip sat down with Astellas chief medical officer Tadaaki Taniguchi to talk about the drug maker’s plans for taking its Claudin18.2-targeting drug to the US market.
![](/-/media/editorial/scrip/2024/06/asco_2024/sc2406_asco_image8_merck_1200.png?rev=9b2ddf9f460a4a8b91dc6ca32e4029b3&w=350&hash=C976F803AA86468BCB8E780D5D5EE36A)
ASCO: Merck Calls V940 IO Strategy ‘Pillar’ Amid Positive Melanoma Data
Follow-up data from Merck & Co./Moderna’s KEYNOTE-942 showed durable responses to V940/Keytruda, while Merck said the therapy plays a leading role in its immuno-oncology strategy.
![](/-/media/editorial/scrip/2024/06/sc2406_set_sail_1775691629_1200.jpg?rev=675e10b930084497a1fcfba58756f6af&w=350&hash=1588205D8398934C2EDA145A6D2C5D0C)
ASCO: GenFleet’s KRAS G12C/EGFR Combo Sets Sail In First-Line NSCLC
Excluding PD-1 inhibitors in its combination strategy for oncology, preliminary results from GenFleet’s Phase II KROCUS study presented at ASCO demonstrate promising efficacy for fulzerasib plus cetuximab in the first-line treatment of KRAS G12C-mutated, advanced non-small cell lung cancer.
![](/-/media/editorial/scrip/2024/06/asco_2024/sc2406_asco_image19_legend_1200.png?rev=5e545270a938444aa752e5c2b666b879&w=350&hash=4C1E04B9AAD8CB1436A924DA05AC60EA)
ASCO: Legend/J&J Explore Carvykti In Community
The companies presented data from CARTITUDE-4 in functional high-risk disease, which has a poorer prognosis, while they are also piloting a program to expand Carvykti’s geographic reach.
![](/-/media/editorial/stock-images/cells/dividingbreastcancercell_royaltystockphoto_149771528_1200x675.jpg?rev=cbd2ce0ae55845f194da9435e4626e88&w=350&hash=421A51B0F4253EDFCD8146A2479598FA)
ASCO: Enhertu’s Empire Expands
“Transformative” data could move Daiichi Sankyo and AstraZeneca’s conjugate into ultralow HER2 expressers, and allow its use ahead of chemo in breast cancer.
![](/-/media/editorial/scrip/2024/06/asco_2024/sc2406_asco_image1_1200.png?rev=ad3f562713534123a2d2f04823a5970d&w=350&hash=4E76588EFEA7E011B0202EE8AA644EB8)
ASCO: NADINA Supports Neoadjuvant IO For Melanoma
The trial offers proof of concept for using Opdivo plus Yervoy as neoadjuvant treatment in melanoma; BMS notes a registrational trial is needed, but it is not clear which IO drugs will advance.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.